Australia · Delayed Price · Currency is AUD Racura Oncology Statistics
Total Valuation
Racura Oncology has a market cap or net worth of AUD 441.16 million. The enterprise value is 406.87 million.
| Market Cap | 441.16M |
| Enterprise Value | 406.87M |
Important Dates
The last earnings date was Wednesday, August 26, 2026.
| Earnings Date | Aug 26, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Racura Oncology has 196.07 million shares outstanding. The number of shares has increased by 3.90% in one year.
| Current Share Class | 196.07M |
| Shares Outstanding | 196.07M |
| Shares Change (YoY) | +3.90% |
| Shares Change (QoQ) | +3.67% |
| Owned by Insiders (%) | 26.99% |
| Owned by Institutions (%) | 2.43% |
| Float | 139.02M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 156.91 |
| PB Ratio | 12.10 |
| P/TBV Ratio | 12.90 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 144.71 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 21.43
| Current Ratio | 21.43 |
| Quick Ratio | 21.28 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -42.28% and return on invested capital (ROIC) is -24.79%.
| Return on Equity (ROE) | -42.28% |
| Return on Assets (ROA) | -23.40% |
| Return on Invested Capital (ROIC) | -24.79% |
| Return on Capital Employed (ROCE) | -28.52% |
| Weighted Average Cost of Capital (WACC) | 8.78% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.10 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +72.00% in the last 52 weeks. The beta is 0.82, so Racura Oncology's price volatility has been lower than the market average.
| Beta (5Y) | 0.82 |
| 52-Week Price Change | +72.00% |
| 50-Day Moving Average | 2.13 |
| 200-Day Moving Average | 2.50 |
| Relative Strength Index (RSI) | 53.61 |
| Average Volume (20 Days) | 76,137 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Racura Oncology had revenue of AUD 2.81 million and -11.09 million in losses. Loss per share was -0.06.
| Revenue | 2.81M |
| Gross Profit | 1.72M |
| Operating Income | -10.40M |
| Pretax Income | -11.09M |
| Net Income | -11.09M |
| EBITDA | -10.12M |
| EBIT | -10.40M |
| Loss Per Share | -0.06 |
Balance Sheet
The company has 34.29 million in cash and no debt, with a net cash position of 34.29 million or 0.17 per share.
| Cash & Cash Equivalents | 34.29M |
| Total Debt | n/a |
| Net Cash | 34.29M |
| Net Cash Per Share | 0.17 |
| Equity (Book Value) | 36.45M |
| Book Value Per Share | 0.19 |
| Working Capital | 33.00M |
Cash Flow
In the last 12 months, operating cash flow was -8.25 million and capital expenditures -3,674, giving a free cash flow of -8.25 million.
| Operating Cash Flow | -8.25M |
| Capital Expenditures | -3,674 |
| Depreciation & Amortization | 281,313 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.25M |
| FCF Per Share | -0.04 |
Margins
| Gross Margin | 61.23% |
| Operating Margin | -369.99% |
| Pretax Margin | -394.38% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Racura Oncology does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.90% |
| Shareholder Yield | -3.90% |
| Earnings Yield | -2.51% |
| FCF Yield | -1.87% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Racura Oncology has an Altman Z-Score of 160.63 and a Piotroski F-Score of 2.
| Altman Z-Score | 160.63 |
| Piotroski F-Score | 2 |